145 citations
- Novartis (Switzerland)CH6 papers
- Roche (Switzerland)CH5 papers
- Merck & Co., Inc., Rahway, NJ, USA (United States)US3 papers
- Boehringer Ingelheim (Germany)DE2 papers
- Columbia UniversityUS2 papers
- GlaxoSmithKline (United States)US2 papers
- Janssen Research & Development (United States)US2 papers
- Nektar Therapeutics (United States)US2 papers
- Pomona CollegeUS2 papers
- University of California SystemUS2 papers
- University of MinnesotaUS2 papers
- AbbVie (Germany)DE1 paper
Showing 2025 · stat.MEShow all
2 papers · 2 filters
stat.ME2025
Monitoring Adverse Events Through Bayesian Nonparametric Clustering Across Studies
Shijie Yuan, Kevin Roberts, Noirrit Kiran Chandra +2
We introduce a Bayesian nonparametric inference approach for aggregate adverse event (AE) monitoring across studies. The proposed model seamlessly integrates external data from his…
stat.ME2025
A robust score test in g-computation for covariate adjustment in randomized clinical trials leveraging different variance estimators via influence functions
Xin Zhang, Haitao Chu, Lin Liu +1
G-computation has become a widely used robust method for estimating unconditional (marginal) treatment effects with covariate adjustment in the analysis of randomized clinical tria…